KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 113 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $312,108 | +7.0% | 32,410 | 0.0% | 0.00% | – |
Q2 2023 | $291,690 | +44.4% | 32,410 | +26.1% | 0.00% | – |
Q1 2023 | $202,002 | +16.3% | 25,700 | 0.0% | 0.00% | – |
Q4 2022 | $173,732 | -29.9% | 25,700 | +50.6% | 0.00% | – |
Q3 2022 | $248,000 | +66.4% | 17,064 | +13.0% | 0.00% | – |
Q2 2022 | $149,000 | -2.6% | 15,100 | +45.2% | 0.00% | – |
Q1 2022 | $153,000 | -5.0% | 10,400 | -14.8% | 0.00% | – |
Q4 2021 | $161,000 | -24.4% | 12,200 | 0.0% | 0.00% | – |
Q3 2021 | $213,000 | -27.1% | 12,200 | 0.0% | 0.00% | – |
Q2 2021 | $292,000 | -18.2% | 12,200 | -35.1% | 0.00% | – |
Q4 2020 | $357,000 | +44.0% | 18,800 | -4.6% | 0.00% | – |
Q3 2020 | $248,000 | +4.2% | 19,700 | 0.0% | 0.00% | – |
Q2 2020 | $238,000 | +153.2% | 19,700 | +60.2% | 0.00% | – |
Q1 2020 | $94,000 | -47.8% | 12,300 | +21.8% | 0.00% | – |
Q4 2019 | $180,000 | +53.8% | 10,100 | 0.0% | 0.00% | – |
Q3 2019 | $117,000 | – | 10,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 589,270 | $8,686,000 | 5.61% |
GREAT POINT PARTNERS LLC | 874,197 | $12,886,000 | 3.11% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 383,233 | $10,805,000 | 2.44% |
Frazier Life Sciences Management, L.P. | 1,572,192 | $23,174,000 | 1.98% |
TANG CAPITAL MANAGEMENT LLC | 648,269 | $9,555,000 | 1.91% |
Deep Track Capital, LP | 1,729,757 | $25,497,000 | 1.64% |
Vivo Capital, LLC | 1,533,559 | $22,605,000 | 1.56% |
Monashee Investment Management LLC | 264,111 | $3,893,000 | 1.13% |
COMMODORE CAPITAL LP | 312,553 | $4,607,000 | 1.03% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,746,300 | $25,740,000 | 0.79% |